TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05729919

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Free gingival graft technique
Description: A horizontal partial thickness incision will be trace at the MGJ to dissect the alveolar mucosa from the keratinized tissue. The alveolar mucosa will be dissected from the underlying periosteum to create an envelope of 4-5 mm apical to the bone dehiscence associated with the gingival recessions. The keratinized tissue coronal to the first incision and neighboring the recession will be de-epithelialized to expose the connective tissue and create a trapezoidal recipient bed having a large apical base at the MGJ and a narrower coronal base just coronal to the CEJ of the experimental units. The grafts will be taken from the palate.The grafts will be positionned with the coronal edge of the CEJ.~Interrupted sutures (6-0 polypropylene, prolene) will be positionned to stabilize the graft. Sling crossed sutures anchored to the periosteum apical to the graft and placed to ensure a tight adaptation of the graft to the root surface
Study: NCT06576466

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Creatine monohydrate
Description: Creatine monohydrate. Guinama brand with CE marking. Code 89823.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dextrinomaltose. Guinama brand with CE marking. Code 91146.
Study: NCT06293937

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Numerical label
Description: Labels that list the amount and percent of daily value of added sugar, sodium, or saturated fat, modeled after Guideline Daily Amounts labels.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interpretive text-only label
Description: Interpretive text-only labels that state when a product contains high amounts of added sugar, sodium, or saturated fat.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interpretive magnifying glass icon label
Description: Interpretive labels that state when a product contains high amounts of added sugar, sodium, or saturated fat, containing a magnifying glass icon.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Separated interpretive magnifying glass icon label
Description: Interpretive labels that state when a product contains high amounts of added sugar, sodium, or saturated fat, containing a magnifying glass icon. Each nutrient will be on a separate label.
Study: NCT05114746

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 177Lu-PSMA-617
Description: administered intravenously at a dose of 7.4 GBq (+/- 10%). A 7.4 GBq dose is equivalent to 200 mCi or 7400 MBq.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 68Ga-PSMA-11
Description: 68Ga-PSMA-11 is manufactured by radiolabeling of PSMA-11 precursor with 68Ga directly at clinical trial sites immediately prior to administration into participants. The 68Ga used for radiolabeling will be eluted from the 68Ge/68Ga generator. 68Ga-PSMA-11 will be prepared as a sterile solution and administered intravenously at a dose of 111 - 185 MBq (3 - 5 mCi).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best supportive/best standard of care
Description: Best supportive/best standard of care as defined by the local investigator (Post taxane population only)
Study: NCT04678401

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Total Myeloid and Lymphoid Irradiation (TMLI) delivered through Radiation Oncology institutional standards

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Total Myeloid and Lymphoid Irradiation (TMLI) delivered through Radiation Oncology institutional standards

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given intravenously -10 to -6 days prior to hematopoietic stem cell transplant (HSCT)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given intravenously -10 to -6 days prior to hematopoietic stem cell transplant (HSCT)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: Given intravenously on day -10 and day- 9 prior to hematopoietic stem cell transplant (HSCT)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: Given intravenously on day -10 and day- 9 prior to hematopoietic stem cell transplant (HSCT)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given intravenously with Mesna on day -8 and day- 7 prior to hematopoietic stem cell transplant (HSCT)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given intravenously with Mesna on day -8 and day- 7 prior to hematopoietic stem cell transplant (HSCT)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: Given intravenously with Cyclophosphamide on day -8 and day -7 prior to hematopoietic stem cell transplant (HSCT)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: Given intravenously with Cyclophosphamide on day -8 and day -7 prior to hematopoietic stem cell transplant (HSCT)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Treg-enriched donor cell
Description: Given intravenously -4 day prior to hematopoietic stem cell transplant (HSCT)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Treg-enriched donor cell
Description: Given intravenously -4 day prior to hematopoietic stem cell transplant (HSCT)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Unmodified donor T Cell
Description: Given intravenously -1 day prior to hematopoietic stem cell transplant (HSCT)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Unmodified donor T Cell
Description: Given intravenously -1 day prior to hematopoietic stem cell transplant (HSCT)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CD34+ Haplo Peripheral Blood Stem Cell
Description: CD34+ Haplo Peripheral Blood Stem Cell Transplantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CD34+ Haplo Peripheral Blood Stem Cell
Description: CD34+ Haplo Peripheral Blood Stem Cell Transplantation
Study: NCT06450106

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STM-416p
Description: STM-416p monotherapy
Study: NCT05400174

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Tilt table (upright position)
Description: Different versions of cognitive assessments will be administered in the supine and upright positions.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Tilt table (upright position)
Description: Different versions of cognitive assessments will be administered in the supine and upright positions.
Study: NCT06016075

Intervention type: DEVICE
Group type: OTHER
Intervention: Hyperpolarised MRI
Description: Hyperpolarised 13C-pyruvate injection while laying in the MRI scanner. Non-radioactive, no risk, approved for use in humans.

Intervention type: DEVICE
Group type: OTHER
Intervention: Sodium MRI
Description: MRI procedure as a regular MRI scan, the only change is us using a different sort of equipment so we are able to detect sodium.

Intervention type: DEVICE
Group type: OTHER
Intervention: Deuterium metabolic imaging (DMI) MRI
Description: Drink of a sugar drink 90min before the MRI scan. Non-radioactive, no risk, approved for use in humans.
Study: NCT06060210

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal Saline
Description: 50-ml Saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: 50-ml volumes, and the ketamine concentration is 1 mg/ml
Study: NCT05196308

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Investigational product administration Xeomin® (MERZ PHARMACEUTICALS GMBH)
Description: Administration of the investigational product.~For the double-blind treatment phase, experimental group :~Patients will receive Xeomin® (MERZ PHARMACEUTICALS GMBH), 100 U, a paired intracavernosal injection to be performed by the investigator.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo administration
Description: For the double-blind treatment phase, control group :~Patients will receive placebo of Xeomin® 100 U, a paired intracavernosal injection is to be performed by the investigator.
Study: NCT06412107

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: True acupressure
Description: Participants will receive a 7-week true self-acupressure practice and a 12-week follow-up.
Study: NCT04812418

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Noctesia
Description: 3 tablets every day at bedtime with a large glass of water
Study: NCT06412107

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham acupressure
Description: Participants will receive a 7-week sham self-acupressure practice and a 12-week follow-up.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Usual care
Description: Routine methods of treatment and care along with an updated education booklet.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Routine methods of treatment and care along with an updated education booklet.
Study: NCT05045534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparison of TB-840 treatment with Placebo
Description: Single dose or Multiple Dose of TB-840 treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparison of TB-840 treatment with Placebo
Description: Single dose or Multiple Dose of TB-840 treatment
Study: NCT04812418

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 tablets every day at bedtime with a large glass of water
Study: NCT05091892

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hydrotherapy programm
Description: Treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hydrotherapy programm
Description: Treatment
Study: NCT05045534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparison of TB-840 treatment with Placebo
Description: Single dose or Multiple Dose of TB-840 treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparison of TB-840 treatment with Placebo
Description: Single dose or Multiple Dose of TB-840 treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparison of TB-840 treatment with Placebo
Description: Single dose or Multiple Dose of TB-840 treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparison of TB-840 treatment with Placebo
Description: Single dose or Multiple Dose of TB-840 treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparison of TB-840 treatment with Placebo
Description: Single dose or Multiple Dose of TB-840 treatment
Study: NCT05724420

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STRIVE course delivery
Description: STRIVE is adapted from the Road to Mental Readiness curriculum, developed by the Department of National Defence in Canada. It is comprised of a 4-hour formal education session where participants are provided knowledge, skills and resources specific to self-assessment for mental wellness and effective mindfulness strategies. High fidelity simulation sessions are then utilized to reinforce and apply mindfulness techniques learned in the formal session..
Study: NCT04917224

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Adaptive Ablative Radiotherapy at 50 Gy (Gray)
Description: Cohort A will include 30 patients with central tumors; the dose regimen prescribed is 50 Gy (Gray) in 5 fractions with a 40 hour inter-fraction interval.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Adaptive Ablative Radiotherapy at 60 Gy (Gray)
Description: Cohort B will include 30 patients with ultra-central tumors; the dose regimen prescribed is 60 Gy (Gray) in 8 fractions on consecutive days.
Study: NCT05731999

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Previct Drugs
Description: Previct Drugs is a new non CE-marked eHealth system intended to be used for future monitoring and treatment of patients with substance use disorder (SUD). Previct Drugs consists of an application (app) to be installed on a smartphone, a web-based careportal to be accessed from a computer by the healthcare professional for administration and access of registered data, and a database for storage, handling, and analysis of reported data. Previct Drugs is intended to be used by healthcare professionals and patients within treatment of SUD.
Study: NCT05801653

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Effects of Oat and Oat Components on Cardiometabolic risk variables
Description: Oat and oat bioactive components consumed as breakfast meal.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Effects of Oat and Oat Components on Cardiometabolic risk variables
Description: Oat and oat bioactive components consumed as breakfast meal.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Effects of Oat and Oat Components on Cardiometabolic risk variables
Description: Oat and oat bioactive components consumed as breakfast meal.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Effects of Oat and Oat Components on Cardiometabolic risk variables
Description: Oat and oat bioactive components consumed as breakfast meal.
Study: NCT05731999

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Previct Drugs
Description: Previct Drugs is a new non CE-marked eHealth system intended to be used for future monitoring and treatment of patients with substance use disorder (SUD). Previct Drugs consists of an application (app) to be installed on a smartphone, a web-based careportal to be accessed from a computer by the healthcare professional for administration and access of registered data, and a database for storage, handling, and analysis of reported data. Previct Drugs is intended to be used by healthcare professionals and patients within treatment of SUD.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Previct Drugs
Description: Previct Drugs is a new non CE-marked eHealth system intended to be used for future monitoring and treatment of patients with substance use disorder (SUD). Previct Drugs consists of an application (app) to be installed on a smartphone, a web-based careportal to be accessed from a computer by the healthcare professional for administration and access of registered data, and a database for storage, handling, and analysis of reported data. Previct Drugs is intended to be used by healthcare professionals and patients within treatment of SUD.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Previct Drugs
Description: Previct Drugs is a new non CE-marked eHealth system intended to be used for future monitoring and treatment of patients with substance use disorder (SUD). Previct Drugs consists of an application (app) to be installed on a smartphone, a web-based careportal to be accessed from a computer by the healthcare professional for administration and access of registered data, and a database for storage, handling, and analysis of reported data. Previct Drugs is intended to be used by healthcare professionals and patients within treatment of SUD.
Study: NCT06412107

Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Description: Routine methods of treatment and care along with an updated education booklet.
Study: NCT04939597

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cognitive Assessment
Description: Complete cognitive testing

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Cognitive Assessment
Description: Complete cognitive testing

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study: NCT06226688

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biofeedback device and other group control group
Description: Intervention 1 :-Using the biofeedback device with dumble to strength affected arm post mastectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Control group
Description: Shoulder mobilization Shoulder ladder ex Shoulder wheel ex Ipc

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Control group
Description: Shoulder mobilization Shoulder ladder ex Shoulder wheel ex Ipc
Study: NCT05656898

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Piezocision+GaALAs diode laser
Description: After seven weeks of piezosurgery, GaALAs diode laser (wavelength: 810 nm and exposure time of 10 seconds\\point) 10 seconds per point will be applied on each tooth of the six maxillary anterior teeth .

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Piezocision
Description: Vertical soft-tissue incisions will be made on the buccal and palatal gingiva. One incision will be made between the roots of the six upper anterior teeth, and two incisions will be made between the upper canines and the second premolars.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Orthodontic fixed appliance
Description: Closed nickel-titanium coil springs applying 250 g of force per side will be used for retraction of the maxillary anterior teeth.
Study: NCT06372054

Intervention type: OTHER
Intervention: Biological sample collection
Description: Collection of biological samples (blood, urine, saliva) and clinical data

Intervention type: OTHER
Intervention: Biological sample collection
Description: Collection of biological samples (blood, urine, saliva) and clinical data
Study: NCT05955495

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Food
Description: Post-operative feeding includes water, liquid diet, soft diet.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food
Description: Post-operative feeding includes water, liquid diet, soft diet.
Study: NCT06273787

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diaphragmatic release
Description: diaphragmatic myofascial release for 1 months 3 sessions per week

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: diaphragmatic release
Description: diaphragmatic myofascial release for 1 months 3 sessions per week
Study: NCT06446310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QLG2198
Description: Participants receive QLG2198 three times a week (0,5 micrograms/kg dry body weight). QLG21988 is administered by intravenous bolus injection into the venous line of the dialysis circuit at the end of each dialysis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QLG2198
Description: Participants receive QLG2198 three times a week (0,5 micrograms/kg dry body weight). QLG21988 is administered by intravenous bolus injection into the venous line of the dialysis circuit at the end of each dialysis.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants receive Placebo three times a week (0,5 micrograms/kg dry body weight). Placebo is administered by intravenous bolus injection into the venous line of the dialysis circuit at the end of each dialysis
Study: NCT05409248

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalized cognitive stimulation
Description: Online gamified activities designed to stimulate cognitive functions (specifically executive function) will be carried out through a mobile application or web browser. Performance feedback will be shown after each activity.
Study: NCT04939597

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine Hydrochloride
Description: Given PO

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Administration
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT05180968

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nabilone 0.5 MG Oral Capsule
Description: This intervention will consist of subjects receiving nabilone 0.5 mg orally at night for 1 week increased to nabilone 0.5mg orally twice a day for 3 weeks. Duration of the intervention will be 4 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Nabilone
Description: This intervention will consist of subjects receiving placebo 1 capsule orally at night for 1 week increased to placebo 2 capsules twice a day for 3 weeks. Duration of the intervention will be 4 weeks.
Study: NCT05805163

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FABI tailored COVID-19 testing pamphlet
Description: FABI adapted COVID-19 educational pamphlet

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard COVID-19 home-based test kit
Description: Standard COVID-19 home-based test kit
Study: NCT05157724

Intervention type: PROCEDURE
Intervention: PLASMA
Description: The aim is to remove the prostatic adenoma by enucleation, i.e. to pass through the plane between the adenoma and the prostatic capsule, as opposed to resection, which also consists of removing the adenoma, but by making small cuts in the prostatic tissue, without necessarily reaching this anatomical plane between the adenoma and the capsule. This means removing less adenoma and therefore increasing the risk of adenomatous regrowth in the long term or obtaining worse results than enucleation in the short to medium term.~The other advantage of using this approach is that it reduces intra- and post-operative bleeding and does not require the systematic discontinuation of anti-aggregating or anticoagulant treatments prior to the operation. The field of indications is thus potentially enlarged.
Study: NCT05805163

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard COVID-19 home-based test kit
Description: Standard COVID-19 home-based test kit
Study: NCT04564430

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Catapresan
Description: The intervention is either a single intravenous bolus of 3mcg/kg Catapresan (150mcg/1ml) or an equal amount of saline at the time of tourniquet inflation.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: controlgroup receiving saline
Study: NCT03886025

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anodal transcranial Direct Current Stimulation (tDCS)
Description: Non-invasive brain stimulation
Study: NCT06088329

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful Walking for Adults with Chronic Pain
Description: Participants identified with chronic pain will complete 6 sessions of mindfulness based walking exercises.
Study: NCT06653101

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: The trial phase of this study lasted 12 weeks, and each patient will make 4 visits (week 0, week 4, week 8, week 12)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The trial phase of this study lasted 12 weeks, and each patient will make 4 visits (week 0, week 4, week 8, week 12)